Medical Meeting

Rethinking Routines in MS Management: What the Future Holds for DMTs and Cognitive Assessment Strategies

Launch Date
03/08/2021
Credit Amount
0.00 Expired
Credit Expires
03/08/2022

Faculty

Tanuja Chitnis, MD, FAAN
Professor of Neurology, Harvard Medical School
Director, Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital
Director, Translational Neuroimmunology Research Center
Director, Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB) Study
Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA
Tanuja Chitnis, MD, FAAN

Dr. Tanuja Chitnis is a Professor of Neurology at Harvard Medical School and Senior Scientist within the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital (BWH), where she created the Translational Neuroimmunology Research Center focused on bringing bench discoveries to clinical trials for multiple sclerosis and related diseases. She is a board-certified neurologist specializing in multiple sclerosis (MS), with a dual appointment as senior neurologist at BWH and Director of the Partners Pediatric MS Center at the Massachusetts General Hospital (MGH) in Boston, Massachusetts, USA. She also serves as the Director of the CLIMB Natural History of MS study at the Partners MS Center at BWH and follows over 2,400 MS patients longitudinally. Here she oversees a team of analysts and postdoctoral fellows working to identify biomarkers precision treatment in MS patients.

Between 2010-2018, Dr. Chitnis served as the elected Chair of the International Pediatric MS Study Group, where she has led several initiatives in the study of MS in children, including the launch of the first clinical trials in this population, leading to the first FDA-approved therapy for this disease. She has authored over 250 publications and reviews related to MS and demyelinating disorders, including the New England Journal of Medicine, Neurology, and Journal of Neuroscience. She receives grant funding from the Department of Defense, National MS Society, and other organizations. She is the recipient of several awards including the 2018 Milestones Award from the National MS Society.

John DeLuca, PhD
Senior Vice President for Research, Kessler Foundation, West Orange, NJ
Professor, Departments of Physical Medicine & Rehabilitation and Department of Neurology, Rutgers New Jersey Medical School
John DeLuca, PhD

John DeLuca, PhD, is the Senior Vice President for Research and Training at Kessler Foundation, a Professor in the Department of Physical Medicine & Rehabilitation, and the Department of Neurology at Rutgers, New Jersey Medical School. He is board certified in Rehabilitation Psychology by the American Board of Professional Psychology. Dr. DeLuca has been involved in neuropsychology and rehabilitation research for over 30 years.

He is internationally known for his research on disorders of memory and information processing in a variety of clinical populations including multiple sclerosis, traumatic brain injury, aneurysmal subarachnoid hemorrhage, and chronic fatigue syndrome. Dr. DeLuca has published over 350 articles, books and book chapters in these areas, has edited 6 books in neuropsychology, neuroimaging and rehabilitation, and is a co-editor for the Encyclopedia of Clinical Neuropsychology. He has received over 38 million dollars in grant support for his research. Dr. DeLuca’s most recent research ventures include the cerebral mapping of human cognitive processes using functional neuroimaging, as well as the development of research-based techniques to improve cognitive impairment. He serves on the editorial boards of many journals and has received numerous national and international awards in recognition of his work.

Lauren B. Krupp, MD
Director, Multiple Sclerosis Comprehensive Care Center, NYU Langone Medical Center
Professor of Neurology, NYU Grossman School of Medicine, New York, NY
Lauren B. Krupp, MD

Lauren Krupp, MD, Professor of Neurology at the NYU Grossman School of Medicine, directs the Multiple Sclerosis (MS) Comprehensive Care Center at NYU Langone Health, which cares for individuals throughout the lifespan with MS and related disorders. Her clinical work focuses on children and adults with MS and her research interests include novel ways for measuring and treating fatigue, brain health, and cognitive function in the home and in the office. Dr. Krupp earned her MD from the Albert Einstein College of Medicine, completed her residency in neurology at Albert Einstein and Montefiore Medical Center, and completed fellowship training in neuroimmunology and MS at the National Institutes of Health. Her research has been supported by National Institutes of Health, Department of Defense, National Multiple Sclerosis Society, and private foundations. Dr. Krupp has more than 175 peer reviewed publications, has worked closely with other national and international leaders in adult and pediatric MS, is the founding chair of the International Pediatric MS Study Group, and sits on steering committees of the US Network of Pediatric MS Centers, the International MS Cognition Society, and the International Pediatric MS Study Group. She is committed to furthering knowledge about MS and providing those with the disease, compassionate, comprehensive, cutting-edge care.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Additional Formats

Statement of Need

Multiple sclerosis (MS) is a chronic inflammatory and neurological disease that is the leading cause of disability in young and middle-aged people in the United States. The number of disease-modifying therapies (DMTs) available for treatment of MS has expanded in recent years, and it is imperative that neurologists and other health care professionals (HCPs) have up-to-date knowledge of clinical efficacy and safety of these therapeutic agents to inform individualized treatment decisions.

Cognitive impairment (CI) is common in patients with MS and contributes substantially to disability, loss of employment, and declines in quality of life, yet CI remains underrecognized. Clinicians need to be aware of recent recommendations for routine assessment and management of CI, deficits typical of MS. CI is increasingly being evaluated in clinical trials of MS therapies, and emerging evidence regarding cognitive effects of DMTs and the relationship between CI and other features of MS progression may have important implications for MS management.

This CME Outfitters webcast will feature an expert panel discussion that focuses on the efficacy and safety of recently approved DMTs, implementing cognitive assessment into routine monitoring for patients with MS, and emerging data on the effects of MS therapies on cognition.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Apply clinical data on efficacy and safety of recently approved therapies to individualized treatment decisions for patients with MS.
  • Incorporate cognitive assessment into routine monitoring for patients with MS.
  • Evaluate emerging data on the effects of MS therapies on cognition.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Examine clinical data on efficacy and safety of recently approved therapies for individualized treatment plans for patients with MS.
  • Describe how to incorporate cognitive assessment into routine monitoring for patients with MS.
  • Evaluate emerging data on the effects of MS therapies on cognition.

Financial Support

Supported by an educational grant from Bristol Myers Squibb Company.

Target Audience

Neurologists, PAs, nurse practitioners, nurses, pharmacists, and other HCPs involved in care of patients with MS.

Credit Information

Physicians (ACCME)

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (CNE)

Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.0 contact hour(s).

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Pharmacists (ACPE)

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit. Jump to Activity UAN.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABPN MOC

ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to PAs

PAs may claim a maximum of .25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit ™ from organizations accredited by ACCME or a recognized state medical society.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Chitnis has no disclosures to report.

Dr. DeLuca reports he received grants from Biogen. He is on the speakers bureau for Biogen. He is a consultant for the Celgene Corporation and Novartis.

Dr. Krupp reports she receives research support from Biogen (PI). She is a consultant for Eisai Inc.; Gerson Lehrman Group, Inc.; Janssen Pharmaceuticals, Inc.; Novartis; Roche; and Sanofi-Aventis.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Michael J. Franks, MSN, AGACNP-BC, FNP-BC (peer reviewer) has no disclosures to report.

Rachel Speer, PhD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-101-H01-P

 

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

 

 

MMV-110-030821-08

Related Activities

Diversity & Inclusion
03/22/2023

Health Inequities in Mental Health Care

0.75
begin Learn More
Neuropsychiatric
05/03/2023

Global Perspectives on Diagnosis and Management of Childhood Epilepsy Disorders

1.00 Hours
Register Learn More
Neuropsychiatric
11/14/2022

Adult Considerations in Spinal Muscular Atrophy: Building Clinician and Patient Medical Teams

1.00 Hours
Begin Learn More
Rethinking Routines in MS Management: What the Future Holds for DMTs and Cognitive Assessment Strategies
Event Date: 03/08/2021
Begin